Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
To examine the efficacy and safety of aripiprazole versus placebo as an adjunctive therapy
co-administered with either an selective serotonin reuptake inhibitor (SSRI) or a
serotonin-norepinephrine reuptake inhibitor (SNRI) in patients with major depressive
disorder.